Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


HIV protease inhibitors

INTRODUCTION

Protease inhibitors (PIs) are potent antiretroviral drugs recommended as part of the "preferred regimen" for patients in the guidelines of the International AIDS Society-USA (IAS-USA) and the Department of Health and Human Services (DHHS) [1,2].

It is important to understand the pharmacology of the protease inhibitors since exposure to low doses of PIs for relatively short periods of time is associated with the development of HIV drug resistance [3,4]. As a result, underdosing, intermittent dosing, non-adherence, and drug malabsorption should be avoided during PI therapy [5]. In addition, these drugs should be taken in combination with other antiretroviral agents.

This topic review will provide information that will highlight the relevant dosing and administration differences between these agents. Some of the information is intended for the prescriber, while patient information and the important drug interactions that can occur are presented elsewhere. (See "Patient information: Tips for taking HIV medications (Beyond the Basics)".)

DOSING AND ADMINISTRATION

Serum concentrations and drug resistance — It is essential to dose the PIs correctly to avoid low serum drug concentrations, which can lead to the development of resistance to an individual agent or cross-resistance to other members of this class. Significant differences in absorption, serum half-lives, routes of metabolism, and dosing frequency exist among the protease inhibitors. For detailed information about PI dosing, see the DHHS Antiretroviral Guidelines for Adults and Adolescents, which can be accessed at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (see Appendix B, Table 3).

The early dose-ranging studies with indinavir, for example, showed maximum antiretroviral effect with ≥2.4 g/day; lower doses were associated with a reduced response, increased resistance, and diminished effectiveness of dose adjustment [3]. Only newly enrolled patients who started therapy at 2.4 g/day showed a sustained, good viral load response, while those who started at too low a dose and later increased their dose did not achieve viral suppression. Subsequent trials have shown that all patients treated with PIs should receive combination antiviral regimens, usually consisting of one to two PIs and two nucleoside reverse transcriptase inhibitors [1,6].

                                                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Feb 5, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 (Accessed on April 06, 2012).
  2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.
  3. Mascolini M. The rolling uncertainties of antiprotease prescribing. J Int Assoc Physicians AIDS Care 1996; 2:6.
  4. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281.
  5. Mascolini M. Protease inhibitors and nucleoside combinations, or, Alice in Gaithersburg. J Int Assoc Physicians AIDS Care 1996; 2:23.
  6. Drugs for HIV infection. Med Lett Drugs Ther 1997; 39:111.
  7. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289.
  8. Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1419.
  9. http://www.fda.gov/Drugs/DrugSafety/ucm230096.htm (Accessed on April 04, 2011).
  10. Pollard RB. Use of proteinase inhibitors in clinical practice. Pharmacotherapy 1994; 14:21S.
  11. Product Information, saquinavir, Roche Laboratories, revised December, 1995.
  12. www.fortovase.com/pdf/FTVDearDoctorFINAL.pdf (Accessed on June 03, 2005).
  13. Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54:785.
  14. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234.
  15. Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006; 20:1401.
  16. George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999; 107:624.
  17. Product information, ritonavir, Abbott Laboratories, revised February, 1996.
  18. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528.
  19. Knox TA, Oleson L, von Moltke LL, et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008; 49:358.
  20. Product information, indinavir, Merck, March, 1996.
  21. Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007; 8:457.
  22. Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006; 42:61.
  23. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401.
  24. Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041.
  25. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47:1324.
  26. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635.
  27. Squires K, et al. 42nd ICAAC 2002, Abstract H1076.
  28. Nieto-Cisneros L, et al. 2nd Conference on HIV Pathogenesis and Treatment, Paris, July 2003, Abstract 117.
  29. Santoro MM, Bertoli A, Lorenzini P, et al. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS 2008; 22:7.
  30. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23:83.
  31. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381.
  32. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729.
  33. McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26:259.
  34. Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41.
  35. Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis 2010; 51:101.
  36. Ribaudo HJ, Daar ES, Tierney C, et al. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 2013; 207:420.
  37. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clin Infect Dis 2012; 55:1270.
  38. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215.
  39. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262.
  40. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010; 24:2019.
  41. Eley T, Zhu L, et al. Effect of omeprazole 20 mg daily on the bioavailability of multidose atazanavir with ritonavir in healthy subjects. International Workshop on Clinical Pharmacology of HIV Treatment, April 16-18, 2007, Budapest, Hungary. Poster 66.
  42. Guaraldi G, Cocchi S, Motta A, et al. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother 2008; 62:1356.
  43. Schake D. How flexible is tipranavir in complex with the HIV-1 protease active site? AIDS 2004; 18:579.
  44. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007; 45:761.
  45. Hoffmann C, Kamps BS (Eds) www.HIVMedicine.com (Accessed on March 08, 2005).
  46. www.aidsmeds.com/drugs/tipranavir.htm (Accessed on March 09, 2005).
  47. "The Pink Sheet" 2005; 67:16.
  48. Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47:429.
  49. Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/r regimen in antiretroviral therapy experienced patients: 24-week data. In: Program and abstracts of the 44th Intersceince Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-1137a.
  50. Cahn P. 24-week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir or an optimized ritonavir-boosted standard of care comparatory PI in a large randomized multicenter trial in treatment-experienced HIV+ patients. In: Program and abstracts of the 7th International Congress of Drug Therapy in HIV infection; November 13-18, 2004; Glasgow, Scotland; Abstract PL143.3.
  51. Katlama C, Walmsley S, Hicks C, et al. Tipranavir achieves twice the rate of treatment responses and prolongs durability of response versus comparator PI in antiretroviral therapy experenced patients, independent of baseline CD4+ cell count or viral load: week 48 RESIST 1 and 2 combined analyses. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic infections. February 5-8, 2006; Denver, Colo. Abstract #520.
  52. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.
  53. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347.
  54. Boehringer Ingelheim Aptivus gets accelerated approval. "The Pink Sheet" 2005; 67:3.
  55. Product Information, Aptivus.
  56. Cooper D, Zajdenverg R, Ruxrungtham K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33 (Abstract PL13.4]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV infection 2006.
  57. www.hivmedicine.com/textbook (Accessed on March 09, 2005).
  58. www.aidsmeds.com (Accessed on March 09, 2005).
  59. Arastéh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005; 19:943.
  60. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314.
  61. Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety at 48 weeks of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1 patients with no darunavir resistance-associated mutations: the Odin trial. In: Program and abstracts of the 17th Conference on Retroviruses and O (Accessed on January 31, 2011).
  62. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929.
  63. Product labeling, Prezista, Tibotec, Inc. December 2010.
  64. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449.
  65. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006; 20:1131.
  66. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827.
  67. Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009; 23:2237.
  68. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127:947.
  69. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127:948.
  70. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881.
  71. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251.
  72. Behrens GM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002; 110:1319.
  73. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.
  74. Vyas AK, Koster JC, Tzekov A, Hruz PW. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 2010; 285:36395.
  75. Tsiodras S, Perelas A, Wanke C, Mantzoros CS. The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications. J Infect 2010; 61:101.
  76. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682.
  77. Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367.
  78. Worm SW, Kamara DA, Reiss P, et al. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205:535.
  79. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17.
  80. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63.
  81. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48.
  82. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137.
  83. Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 2010; 63:549.
  84. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349.
  85. Darunavir (Prezista) for HIV infection. Med Lett Drugs Ther 2006; 48:74.
  86. http://www.hivandhepatitis.com/recent/2008/031208_a.html (Accessed on February 18, 2011).
  87. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336:138.
  88. Daudon M, Estépa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349:1294.
  89. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119.
  90. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162:1493.
  91. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113.
  92. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569.
  93. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671.
  94. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871.
  95. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV infection convened by the DHHS and the Henry J. Kaiser Family Foundation. August 13, 2001.
  96. Hayman M, Seidl EC, Ali M, Malik K. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole. Pharmacotherapy 2003; 23:1190.
  97. Al-Khafaji AH, Dewhirst WE, Manning HL. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg 2002; 94:1583.
  98. Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 2000; 343:815.
  99. Nelfinavir Product Information, Agouron Pharmaceuticals, 1997 (also reprinted in 1998 PDR).
  100. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74.
  101. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345:952.
  102. Hicks C. RESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 2004, Washington, D.C.
  103. www.hivandhepatitis.com/2004icr/7thcongress/posters/resist1.pdf (Accessed on March 09, 2005).
  104. Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 2005; 19:1393.
  105. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis 2006; 6:215.
  106. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333.
  107. Haas DW. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis 2006; 42:1197.
  108. Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS 2009; 23:357.
  109. Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009; :CD007268.
  110. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189.
  111. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13:963.